MYOK - MyoKardia: Safe But Fleeting Expected Annualized Return Of 6.13%
- Bristol-Myers is acquiring MyoKardia for $225.
- HSR-waiting period passed yesterday.
- The deal could close within the next two weeks.
- Annualized returns is quite attractive while odds of a deal break are low.
For further details see:
MyoKardia: Safe But Fleeting Expected Annualized Return Of 6.13%